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Myeloid leukocytes are essentially involved in both tumor progression and control. We show
that neo-adjuvant treatment of mice with an inhibitor of CSF1 receptor (CSF1R), a drug that
is used to deplete tumor-associated macrophages, unexpectedly promoted metastasis.
CSF1R blockade indirectly diminished the number of NK cells due to a paucity of myeloid
cells that provide the survival factor IL-15 to NK cells. Reduction of the number of NK cells
resulted in increased seeding of metastatic tumor cells to the lungs but did not impact on
progression of established metastases. Supplementation of mice treated with CSF1R-
inhibitor with IL-15 restored numbers of NK cells and diminished metastasis. Our data
suggest that CSF1R blockade should be combined with administration of IL-15 to reduce
the risk of metastasis.
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Introduction
Despite recent advances in oncology, metastatic disease remains the major cause of  cancer-related death. 
The cascade of  events involved in this process includes invasion of  surrounding tissue, intravasation into 
the blood or lymph vasculature, survival in the circulation, and extravasation into and colonization of  dis-
tant tissue. Each of  these steps involves crosstalk between tumor cells and hematopoietic cells, including 
lymphocytes and different cell types of  myeloid origin (1).
NK cells primarily control circulating tumor cells (2), while CD8+ T cells can control transformed cells in 
primary tumors, as well as in metastatic lesions (3). CD8+ T cells became an attractive target for immune-ac-
tivating therapies (4, 5), and approaches to boost NK cell responses are under development (6). Progress in 
therapeutic strategies targeting the myeloid compartment has proven more complicated due to the dual role 
these cells play in tumor progression and metastasis. On the one hand, myeloid cells can produce proinflam-
matory cytokines and survival factors for NK and T cells, such as IL-2, IL-12, and IL-15 (7–9), and comprise 
antigen-presenting cells (APCs) that are crucial to T cell activation (10). On the other hand, they are recruited 
to tumors, where they contribute to local immunosuppression, promote tumor growth, and directly facilitate 
formation of metastases (11–13). Targeting tumor-associated macrophages (TAMs) by inhibition of CSF1R 
has shown promising results in preclinical cancer models (14–17) and in diffuse-type tenosynovial giant cell 
tumors, which are driven by CSF1 in an autocrine manner (18). Data on CSF1R blockade in malignant disease 
including metastasis are largely pending (19). However, little is known about the impact of such treatment on 
the formation or progression of metastasis. Here, we aimed to answer this question and investigated the impact 
of CSF1R blockade on metastasis when given as a monotherapy in a neo-adjuvant or adjuvant setting.
Results
Targeting CSF1R+ myeloid cells promotes metastatic disease. We used a model of  spontaneous metastasis 
from resected, primary Lewis lung carcinoma tumors expressing luciferase (LLC-LUC) in immuno-
competent mice. Within 3 weeks after tumor resection, approximately 50%–70% of  mice develop 
metastases preferentially in the lungs, liver, or tumor-draining lymph nodes as detected by biolumines-
cent imaging. Macrophages, defined as CD45.2+CD11b+Ly6G–F4/80+Ly6Cint cells, build the majority 
of  tumor-infiltrating leukocytes (Supplemental Figure 1; supplemental material available online with 
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this article; https://doi.org/10.1172/jci.insight.97792DS1) and were shown to play a tumor-promoting 
role (11–13). All TAMs express CSF1R as well as CD206, Egr2, MHC class II, and low amounts of  
iNOS (data not shown), suggesting an M2-like phenotype. To address the impact of  macrophages on 
the development of  metastasis, we used BLZ945, a small-molecule inhibitor that blocks CSF1R-signal-
ing (CSF1R inhibitor; CSF1Ri) and thus prevents the development and maintenance of  various myeloid 
cell subsets, including CSF1R-expressing TAMs (16, 20). In order to investigate the contribution of  
CSF1R+ myeloid cells on the initial stages of  the metastatic cascade, we administered CSF1Ri from the 
time of  tumor cell injection until the resection of  the primary tumor (neo-adjuvant treatment, Figure 
1A). Administration of  CSF1Ri did not influence the growth of  the primary tumor, as illustrated by the 
size at resection (Figure 1B). In contrast, a significantly higher proportion of  mice treated with neo-ad-
juvant CSF1Ri developed metastases than control mice treated with the vehicle, 20% Captisol (Figure 
1C). We blocked CSF1R in the 4T1 model of  spontaneous metastasis from breast cancer in BALB/c 
mice using CSF1Ri or antibody-mediated blockade of  CSF1R before resection of  the primary tumor 
(Figure 1D) and again observed that CSF1R blockade had no impact on the weight of  the primary 
Figure 1. Blocking CSF1R increases 
the risk of developing metastat-
ic disease. (A–C) Spontaneous 
metastasis from s.c. LLC-LUC 
tumors in C57BL/6 mice. (A) 
Experimental timeline. (B) Primary 
tumor size at resection. Mean 
± SD. Each symbol represents 
an individual mouse (Ctrl, n = 7; 
CSF1Ri, n = 6). Representative 
data from 2 independent experi-
ments are shown. (C) Metastatic 
burden presented as sum of lumi-
nescent signals from lung, liver, 
and both tumor-draining lymph 
nodes for each mouse. Filled 
circles represent mice with detect-
able metastasis; open circles 
represent metastasis-free mice. 
Mice above the dotted line had to 
be sacrificed before the end-
point due to metastatic burden. 
Numbers above the graph show 
number of mice with metastasis in 
total cohort of animals. *P < 0.05 
(χ2 test). Pooled data from 2 inde-
pendent experiments are shown 
(Ctrl, n = 13; CSF1Ri, n = 17). (D–F) 
Spontaneous lung metastasis 
from autochthonous 4T1 tumors 
in BALB/c mice. (D) Experimental 
timeline. Mice were treated daily 
with a small-molecule inhibitor of 
CSF1R (E) or with blocking anti-CS-
F1R antibody on the indicated 
days (F). (E and F) Primary tumor 
weight at resection. Mean ± SD. 
Lung metastases quantified by 
bioluminescence. Mean ± SEM. *P 
< 0.05 (2-tailed Student’s t test 
with Welch’s correction). Each 
symbol represents an individual 
mouse. (E) Ctrl, n = 9; CSF1Ri, n = 
10. (F) Ctrl and CSF1Ri, n = 11.
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tumor but resulted in increased metastasis to the lungs (Figure 1, E and F). Also, in the context of  4T1 
breast cancer, CSF1R blockade significantly reduced the number of  circulating NK cells (Supplemental 
Figure 2, A–C). Our observation that CSF1R blockade does not influence the growth of  the primary 
tumor in different experimental setups is in agreement with recently published findings (21). Because 
4T1 cells metastasize to the lungs before resection is required for ethical reasons, we have blocked 
CSF1R-using antibodies and analyzed subsequent lung metastasis without resection of  the primary 
tumor (Supplemental Figure 3A). Also with continuous presence of  the primary tumor — whose size 
was not affected by CSF1R blockade (Supplemental Figure 3B) — anti-CSF1R resulted in increased 
metastatic load in the lungs (Supplemental Figure 3C).
As resection of  the primary tumor removes the source of  circulating, metastasizing tumor cells, which 
have short half-lives in the circulation (22), we administered CSF1Ri immediately after resection until 
the endpoint (adjuvant treatment) to investigate the impact of  CSF1R+ cells on metastatic outgrowth and 
found that adjuvant CSF1Ri had no impact on metastasis (Supplemental Figure 4).
Together, these results suggest that systemic blockade of  CSF1R in a neo-adjuvant setting increases the 
risk of  developing metastasis.
Systemic inhibition of  CSF1R-signaling affects NK cell homeostasis and promotes metastatic seeding. To under-
stand why CSF1R blockade promotes metastasis, we determined the numbers of  tumor-associated and 
circulating leukocytes in mice treated with CSF1Ri. As expected, treatment of  tumor-bearing mice with 
CSF1Ri reduced the numbers of  tumor-associated monocytes and macrophages (Figure 2A and Supple-
mental Figure 5A), as well as the number of  circulating Ly6Chi and Ly6Clo monocytes (Figure 2B). Treat-
ment with CSF1Ri also resulted in decreased numbers of  tumor-associated and circulating NK cells, as 
well as CD8+ T cells (Figure 2, A and B), whereas the numbers of  neutrophils, B cells, and CD4+ T cells 
were not affected (Figure 2B). This was independent of  the presence of  a tumor, since treatment with 
CSF1Ri in non–tumor-bearing mice also significantly reduced the number of  circulating Ly6Chi and Ly6Clo 
myeloid and NK cells, and showed a tendency of  less CD8+ cells (Supplemental Figure 5B). CSF1Ri result-
ed in a selective loss of  CSF1R+ cells from the CD11b+ population both in tumor and blood (Figure 2C). 
The apparent discrepancy regarding NK and CD8+ T cell numbers between Figure 2 and Supplemental 
Figure 3B may be caused by the fact that we treated mice with CSF1Ri for 7 days in Figure 2 and only for 
5 days in Supplemental Figure 5B; furthermore, this can be explained by variation between experiments, 
mainly because of  sample processing. In fact, the percentage of  CD8+ as well as the percentage of  NK cells 
of  live CD45+Lin– cells in the control group was similar in both experiments (data not shown). In contrast, 
CSF1Ri did not show a measurable effect on the number of  circulating neutrophils, CD4+ T cells, or B cells 
(Supplemental Figure 5C). Treatment with a CSF1R-blocking antibody induced similar changes in the 
number of  circulating total, Ly6Chi, and Ly6Clo monocytes, as well as NK cells (Supplemental Figure 5D), 
but did not affect the number of  CD8+ T cells (not shown).
In addition to depleting monocytic cells, CSF1R blockade also affects the number of  CD8+ T and NK 
cells; therefore, we investigated the contribution of  those effector cells to controlling metastasis. As CSF1Ri 
did not promote metastasis when the treatment was started after resection (Supplemental Figure 4), we 
speculated that CD8+ T or NK cells control the seeding of  circulating tumor cells. For this reason, we used 
i.v.-injected tumor cells as a model, as it eliminates potential effects of  the primary tumor other than pro-
viding metastasizing tumor cells. To study whether T cells play a role in controlling metastatic seeding, we 
depleted CD4+ or CD8+ cells prior to i.v. injection of  LLC-LUC cells and compared the metastatic load in 
the lungs 1 day later. We observed a similar tumor cell load in the lungs in all groups (Figure 3A, left panel) 
and concluded that T cells play no detectable role in the metastatic seeding of  circulating tumor cells to the 
lungs. To exclude a role for CD8+ T cells in controlling metastatic outgrowth, we compared the metastatic 
load in the lungs between CD8+-depleted and control mice 16 days after i.v. injection and observed no dif-
ference (Figure 3A, right panel). A single injection of  anti-CD8 resulted in depletion of  circulating CD8+ T 
cells for at least 18 days (Supplemental Figure 6). Collectively, these results exclude a role for CD8+ T cells 
in controlling metastatic seeding and outgrowth.
We therefore speculated that the increased proportion of  mice with metastasis after CSF1Ri treatment 
is the consequence of  the concomitant loss of  NK cells. To directly address whether NK cells mainly 
eliminate circulating tumor cells or also interfere after metastatic seeding has occurred, we depleted NK 
cells prior to or 24 hours after i.v. injection of  LLC-LUC cells and compared the metastatic load in the 
lungs 14 days later. Tumor cells extravasate and are cleared from the circulation within 24 hours after i.v. 
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Figure 2. Administration of CSF1Ri results in concomitant loss of NK cells. Administration of CSF1Ri starting 8 days before resection results in 
loss of NK, CD8+, and myeloid cells in the tumor (A) and blood (B) as measured by flow cytometry. Ly6Chi and Ly6Clo cells represent inflammatory 
and patrolling monocytes, respectively. Monocytes, CD45.2+CD11b+CSF1R+; NK cells, CD45.2+CD3–NK1.1+; CD8+ T cells, CD45.2+CD3+CD8α+; neutrophils, 
CD45.2+CD11b+Ly6G+; B cells, CD45.2+CD19+; CD4+ T cells, CD45.2+CD3+CD4+. Analysis was performed after gating on live singlets. (C) Administration of 
CSF1Ri starting 8 days before resection results in selective loss of CSF1R+ cells from the CD11b+ population in the blood (left panels) and tumor (right 
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injection (2). Depletion of  NK cells before i.v. injection resulted in significantly increased tumor burden 
in the lungs, whereas depletion after i.v. injection had no impact on metastasis (Figure 3B). The increased 
tumor burden in the lung as a result of  prior NK depletion was already apparent as early as 20 minutes 
after i.v. injection of  LLC-LUC cells (Figure 3C, left panel). Although the tumor load decreased between 
20 minutes and 24 hours after injection of  tumor cells independently of  NK cell depletion, the NK cell–
dependent difference remained (Figure 3C).
NK cells also control spontaneous metastasis, since depletion of  NK cells shortly before surgery result-
ed in a significantly higher proportion of  mice with metastasis (Figure 3D).
Finally, to determine whether CSF1Ri-induced reduction of  NK cell numbers explains the increased 
metastatic burden that we observed after CSF1Ri administration, we directly compared metastatic seeding 
in mice that were treated for 3 days with CSF1Ri or were depleted of  NK cells using anti-NK1.1. Both 
treatments significantly reduced the number of  circulating NK cells. Whereas no NK cells were detectable 
after anti-NK1.1 treatment, we still detected NK cells in CSF1Ri-treated mice (Figure 3E, left panel). Both 
treatments significantly increased metastatic seeding, but NK-depleted mice showed higher metastatic bur-
den than CSF1Ri-treated mice (Figure 3E, right panel), suggesting a correlation between circulating NK 
cell counts and protection against metastatic seeding.
Together, these results indicate that NK cells — and not T cells — are essential to prevent metastatic 
seeding but are dispensable for metastatic outgrowth of  seeded tumor cells.
Administration of  exogenous IL-15 during CSF1Ri treatment restores NK cell numbers and metastasis control. We 
observed that CSF1R blockade results in an expected reduction of  CSF1R-dependent myeloid cells, as well 
as in a rather unexpected loss of  NK and CD8+ T cells. Homeostasis of  NK and CD8+ T cells depends on 
cross-presentation of  IL-15 by IL-15Rα–expressing cells. Because IL-15Rα is expressed by CSF1R positive 
cells, we reasoned that losing such cells reduces the amount of  IL-15 available to CD8+ T and NK cells 
(23–27). Because the concentration of  IL-15 in vivo is too low to detect and expression of  the transpre-
senting IL-15Rα chain under steady state conditions is virtually undetectable (27), we performed an IL-15 
transpresentation assay using phosphorylation of  Stat5 (pStat5) in NK cells as a readout for signaling via 
the IL-15R. We observed that both CD11b+CD115+ and CD11b+CD115– induced pStat5 in NK cells. This 
was dependent on transpresented IL-15, as we detected virtually no pSTAT5 in NK cells that were incu-
bated with CD11b+CD115+ or CD11b+CD115– cells sorted from Il15ra–/– mice (Supplemental Figure 7). In 
mice treated with CSF1Ri or anti-CSF1R, CD11b+CD115+ myeloid cells — which make up a substantial 
proportion of  the cells that transpresent IL-15 — are lost. Consequently, we suggest that the reduction of  
NK cells could be a result of  diminished transpresentation of  IL-15.
To address whether restoration of  NK cell numbers during treatment with CSF1Ri reverts increased 
metastasis, we treated mice with CSF1Ri and supplemented 1 group with IL-15/IL-15Rα complexes 
(IL-15c) (Figure 4A), thus rescuing NK cell numbers in the face of  low numbers of  CSF1R-depen-
dent myeloid cells. Control groups were treated with vehicle or vehicle plus IL-15c. The numbers of  
CSF1R-dependent myeloid cells remained low in CSF1Ri-treated mice supplemented with IL-15c (Sup-
plemental Figure 8A) (28, 29). CSF1Ri-treated mice showed strongly reduced NK cell counts, whereas 
CSF1Ri-treated mice that received exogenous IL-15c or mice that received IL-15c plus vehicle showed 
supraphysiological numbers of  NK cells at the time point of  i.v. injection of  tumor cells (Figure 4B). 
Decreased numbers of  NK cells correlated with increased metastatic load in the lungs, whereas IL-15c–
treated mice developed less metastasis (Figure 4, C and D).
We investigated whether the administration of  IL-15c influenced NK cell maturation or activation. 
Exogenously administered IL-15c did not change the expression of  CD69 or FasL (CD95) by NK cells, but 
it led to a slightly reduced the expression of  DNAM1 (CD226) and an increased expression of  KLRG1 (Sup-
plemental Figure 8B). Furthermore, we found a higher proportion of  less differentiated (CD27+CD11b+) 
and a lower proportion of  terminally differentiated (CD27–CD11b+) NK cells in mice that received IL-15c 
(Supplemental Figure 8C) The relevance of  these findings in the context of  protection against metastatic 
seeding is difficult to interpret at this point because both CD27+CD11b+ and CD27–CD11b+ NK cells can 
execute this function (30, 31).
panels). CSF1R expression was visualized using CSF1R-reporter mice (MacGreen). (A–C) Each symbol represents an individual mouse. (A) Ctrl and 
CSF1Ri, n = 11. (B and C) Ctrl and CSF1Ri, n = 7. Mean ± SD. **P < 0.01, ***P < 0.005 (2-tailed Student’s t test with Welch’s correction). A representa-
tive experiment of 2 is shown.
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Figure 3. Administration of CSF1Ri promotes metastasis via concomitant loss of NK cells. (A) LLC-LUC cells were i.v. injected into C57BL/6 mice that 
were depleted of CD4+ or CD8+ cells. The metastatic burden was determined 24 hours (endpoint 1) or 16 days (endpoint 2) after tumor cell injection by 
bioluminescent imaging on resected lungs. Each symbol represents an individual mouse. Endpoint 1, Ctrl and aCD4, n = 4; aCD8, n = 5. Endpoint 2, Ctrl, 
n = 8; aCD8, n = 6. Mean ± SD. Groups are not statistically significantly different (1-way ANOVA with Bonferroni’s correction). (B) LLC-LUC cells were i.v. 
injected into C57BL/6 mice that were depleted of NK cells immediately before or afterward. The metastatic burden was determined 14 days after tumor 
cell injection by bioluminescent imaging on resected lungs. Each symbol represents an individual mouse. Ctrl and +24 hours, n = 6; –24 hours, n = 5. Mean 
± SD. **P < 0.01 (one-way ANOVA with Bonferroni’s correction). (C) LLC-LUC cells were i.v. injected into NK cell–depleted C57BL/6 mice. The metastat-
ic burden was determined 20 minutes and 1 hour after tumor cell injection by bioluminescent imaging on resected lungs. Each symbol represents an 
individual mouse. Twenty minutes, Ctrl, n = 5; aNK1.1, n = 6. Twenty-four hours, Ctrl, n = 3; aNK1.1, n = 4. Mean ± SD. *P < 0.05 (2-tailed Student’s t test 
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Because the number of  CD8+ T cells also depends on transpresented IL-15, we investigated a possible 
contribution of  CD8+ T cells to the IL-15c–mediated protection against metastasis promoted by blocked 
CSF1R. Therefore, we administered IL-15c to CSF1Ri-treated mice that were or were not depleted of  
CD8+ T cells. We observed that IL-15c protected against CSF1Ri-induced metastasis independently of  
CD8+ T cells (Supplemental Figure 9).
Finally, to further strengthen the point that the number of  circulating NK cells is a major fac-
tor influencing the metastatic load in the lungs, we directly corrected the number of  circulating NK in 
CSF1Ri-treated mice by adoptively transferring sorted NK cells. Adoptively transferred NK cells reduced 
the metastatic load in CSF1Ri-treated mice to that in untreated mice (Figure 5).
Thus, we conclude that CSF1Ri blockade induces a loss of  NK cells secondary to paucity of  IL-15 
transpresenting myeloid cells, which promotes metastasis to the lungs.
Discussion
Tumor-associated, CSF1R-dependent macrophages promote tumor progression, restrict antitumor immu-
nity, and support tumor cells during all stages of  the metastatic cascade (13, 32). This is further under-
lined by the observation that tumors often sustain macrophage differentiation and survival by producing 
CSF1 (33–35). CSF1R has, thus, become an attractive therapeutic target, and CSF1R blockade has yield-
ed promising results in preclinical and clinical studies (14–16, 18, 36, 37). For example, CSF1R blockade 
retards the development of  primary tumors and promotes CD8+ T cell–mediated antitumor immunity 
(14, 16, 38). Furthermore, CSF1R inhibition synergizes with checkpoint blockade therapy in controlling 
primary tumor lesions (15, 39).
Because most studies have focused on how CSF1R blockade influences progression of  primary tumors, 
little is known about the effect of  CSF1R blockade on metastasis. We addressed this question using clin-
ically relevant models for spontaneous metastasis. We applied CSF1R blockade before (neo-adjuvant) or 
after (adjuvant) resection of  the primary tumor. Neo-adjuvant CSF1R blockade had no impact on the 
progression of  primary tumors but unexpectedly promoted metastasis, whereas adjuvant treatment had no 
effect on metastasis.
One other study previously reported the metastasis-promoting effect of  CSF1R blockade (40). The 
authors showed that CSF1R blockade in tumor-bearing mice results in an increased concentration of  
granulocyte CSF (G-CSF) in the serum and, thus, proposed G-CSF–induced neutrophilia as the main 
cause of  increased metastasis (40), although they did not experimentally test this hypothesis. Neutro-
philia is observed in many preclinical cancer models, including 4T1 and LLC, and is a consequence of  
tumor-derived G-CSF (2, 41, 42). A further increase of  neutrophil counts downstream of  CSF1R block-
ade, however, may be a peculiarity of  certain tumors, as we did not observe a BLZ945-induced increase 
of  neutrophil counts in tumor-bearing (LLC-LUC) or naive mice upon treatment with BLZ945. Also, 
blocking CCL2 increases the risk of  developing metastasis upon treatment cessation due to enhanced 
angiogenesis and monocyte counts (43). Thus, targeting myeloid cells in cancer may be less straight-
forward than thought, and therefore, a better understanding of  the role of  different myeloid subsets in 
various aspects of  cancer development and progression is urgently needed.
Here, we offer a mechanistic explanation for the apparently controversial effects of  CSF1R blockade 
in the context of  cancer (14, 16, 39, 40) by discovering that treatment with CSF1Ri concomitantly reduces 
NK cell counts. Maintenance of  peripheral NK cells crucially depends on IL-15, as IL-15R signaling con-
trols the intracellular levels of  antiapoptotic Bcl-2 (44). NK cells express IL-15Rβ/γ, which binds IL-15 
with high affinity only when it is transpresented on IL-15Rα expressed by myeloid cells (23, 24, 26). We 
observed that the detrimental effect of  CSF1R blockade on metastasis is reversed by exogenous IL-15c (28, 
with Welch’s correction). (D) Mice bearing s.c. LLC-LUC tumors were depleted from NK cells before resection. Lower left panel: Number of NK cells in 
the resected tumor. Each symbol represents an individual mouse. Ctrl and aNK1.1, n = 8. Mean ± SD. *P < 0.05 (2-tailed Student’s t test with Welch’s 
correction). Lower right panel: Spontaneous metastasis to the lungs is presented as sum of luminescent signals from lung, liver, and both tumor-drain-
ing lymph nodes for each mouse. Filled circles represent mice with detectable metastasis; open circles represent metastasis-free mice. Mice above the 
dotted line had to be sacrifice before the endpoint due to metastatic burden. Numbers above the graph show number of mice with metastasis in total 
cohort of animals (Ctrl and aNK.1.1, n = 14). **P < 0.01 (χ2 test). (E) Metastatic seeding to the lungs measured 1 day after i.v. injection of LLC-LUC cells into 
NK cell–depleted, CSF1Ri-treated, or control mice. The left panel shows the number of circulating NK cells at day 0. The right panel shows the metastat-
ic burden to the lungs measured by bioluminescent imaging on resected lungs. Each symbol represents an individual mouse. Ctrl, n = 9; aNK.1.1, n = 4; 
CSF1Ri, n = 9. Mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005 (1-way ANOVA with Bonferroni’s correction). A representative experiment of 2 is shown.
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29), which restores the number of  NK cells in the face of  low numbers of  CSF1R-dependent myeloid cells. 
Transpresented IL-15 is also required for survival of  CD8+ memory T cells (24, 45). In fact, our observation 
that CSF1R blockade resulted in a paucity of  both NK and CD8+ T cells supports our explanation that loss 
of  IL-15–transpresenting myeloid cells is indirectly responsible for increased metastasis. Although CSF1Ri 
reduced CD8+ T cell counts, we do not think that CD8+ T cells play a major role in protection against 
metastatic seeding and progression, as depletion of  CD8+ T cells had no impact on these parameters in the 
experimental systems investigated here.
Together, these data show that NK cells are essential for protection against metastatic seeding and, at 
the same time, challenge the notion of  a major role for myeloid cells other than supporting NK cell survival. 
This may seem to contradict the recently published findings by Hanna et al., who showed that control of  
metastasis required the presence of  NR4A1+ patrolling monocytes (46). NR4A1+ patrolling monocytes are 
Ly6Clo monocytes (47) that are enriched in the microvasculature of  the lung. Although this study showed 
that NR4A1+ patrolling monocytes attract NK cells, a functional role for NK cells in protection against 
metastasis was not addressed. We did not specifically investigate NR4A1+ monocytes here but expect that 
CSF1Ri will target NR4A1+ monocytes, as well, because of  their expression of  CSF1R (46). Furthermore, 
and as discussed above, the fact that supplementation with IL-15c prevents CSF1Ri-induced metastasis 
clearly identifies NK cells as the major cell type protecting against metastasis to the lung.
The importance of  NK cells in controlling metastasis after i.v. injection of  tumor cells has been doc-
umented (2, 48–50), which suggests that NK cells protect against metastatic seeding by controlling cir-
culating tumor cells. Circulating tumor cells may be particularly vulnerable to NK cells, as oxidative or 
shear stress can induce increased expression of  ligands for NKG2D on tumor cells (51, 52). We did not 
Figure 4. Exogenous IL-15 prevents CSF1Ri-induced loss 
of NK cells and metastasis. (A) Experimental timeline. 
(B) Number of circulating NK cells defined as CD45.2+CD3–
NK1.1+NKp46+ live singlets on day 3. Each symbol represents 
an individual mouse. Ctrl, n = 9; CSF1Ri, n = 10; IL-15c, n = 5; 
CSF1Ri + IL-15c, n = 5. Mean ± SD. ***P < 0.005 (1-way ANO-
VA with Bonferroni’s correction). A representative experi-
ment of 2 is shown. (C) Quantification of tumor burden in 
the lungs by bioluminescence. Each symbol represents an 
individual mouse. Ctrl, n = 9; CSF1Ri, n = 10; IL-15c, n = 5; 
CSF1Ri + IL-15c, n = 5. Mean ± SEM. *P < 0.05 (1-way ANOVA 
with Bonferroni’s correction). A representative experiment 
of 2 is shown. (D) Representative bioluminescence images 
of resected lungs at the endpoint.
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investigate here which effector mechanisms NK cells employ to protect against metastatic seeding because 
there is a consensus in the literature that the dominant effector mechanism NK cells use to protect against 
metastasis depends on the experimental setting (53–56).
Our findings that neo-adjuvant CSF1Ri promotes metastasis is of  clinical relevance because of  ongoing 
clinical studies on CSF1R-targeting therapies. Ries et al. showed that anti-CSF1R treatment induced a clin-
ical response in patients with nonmetastasizing diffuse-type giant cell tumors, a tumor that produces large 
amounts of  macrophage CSF (M-CSF) (14), but clinical data on CSF1R blockade and metastasis are not yet 
available. However, it has been shown that NK cells protect against metastatic seeding of  human cancer cell 
lines in immunodeficient mice (57) and that homeostasis of  human NK cells requires transpresentation of  
IL-15 by myeloid cells (58). Thus, the available evidence strongly suggests that the crosstalk between NK and 
CSF1R+ myeloid cells, the dependence of  NK cells on transpresented IL-15, and the control of  metastatic 
seeding follow similar mechanisms in mice and humans.
It should be emphasized, however, that — in our experiments — CSF1Ri-induced metastasis only 
occurred in a neo-adjuvant setting. Moreover, we have used CSF1Ri as a monotherapy, not precluding 
the beneficial results of  combining CSF1Ri with other immunotherapeutics. Thus, although blockade 
of  CSF1R signaling depletes myeloid cells including TAMS, and may consequently impede tumor pro-
gression, it can also promote metastasis when used as neo-adjuvant treatment. This relates to CSF1Ri as 
neo-adjuvant treatment but presumably also to situations in which micrometastases or metastases are pres-
ent. Taken together, our results suggest that treatment with CSF1Ri or CSF1R-blocking antibodies bears 
the risk of  increasing metastatic disease in particular conditions, which can be efficiently counteracted by 
concomitant administration of  an NK cell survival factor such as IL-15 (Figure 6).
Methods
Mice. C57BL/6JOlaHsd1 mice were obtained from Harlan Laboratories (Envigo) and BALB/cJRj mice 
from Janvier. Il15rafl/fl (59), CMV-Cre (60), and MacGreen (61) mice were obtained from the Jackson 
Laboratory. Il15rafl/fl and CMV-Cre mice were interbred to obtain Il15ra-deficient mice (referred to here 
as Il15ra–/–). Mice were kept under specific pathogen-free conditions at the Laboratory Animal Services 
Center at the University of  Zurich or ETH Phenomics Center at the Swiss Federal Institute of  Technology 
Zurich (Zurich, Switzerland). Six- to 8-week-old female mice were used for all experiments.
Cell lines. LLC1 cells were obtained from ATCC. 4T1 cells were a gift from Michael Detmar (Swiss 
Federal Institute of  Technology in Zurich). LLC and 4T1 cells were cultured in DMEM supplemented 
with 10% FBS, 2 mM L-glutamine, penicillin, and streptomycin or RPMI 1640 Medium supplemented 
with 10% FBS, 2 mM L-glutamine, penicillin, and streptomycin (all Invitrogen), respectively. LLC cells 
were lentivirally transduced to express firefly LUC–generating LLC-LUC cells; 4T1 cells were lentiviral-
ly transduced to express LUC. Viral particles were a gift from Christian Münz (University of  Zurich). 
Cell lines were confirmed to be free of  Mycoplasma and various viruses by Charles River Research Ani-
mal Diagnostic Services.
Models of  metastasis. For spontaneous metastasis from LLC-LUC tumors, C57BL/6 mice were inject-
ed s.c. with 2 × 105 LLC-LUC cells in 100 μl PBS. After 25–28 days, mice were anesthetized with 2.5% 
Attane (Isoflurane, Piramal Healthcare Ltd.) and 0.04 mg/kg fentanyl (Kantonsapotheke Zurich) injected 
i.p. Primary tumors were subsequently resected, and wounds were clipped with Autoclip wound clips 
Figure 5. Adoptive transfer of NK cells reverts CSF1Ri-induced metastasis. Three groups of C57BL/6 
were treated essentially as described in Figure 4A. Group 1 received daily vehicle starting at day –5 
and LLC-LUC on day 0; group 2 received daily CSF1Ri starting at day –5 and LLC-LUC on day 0; group 
3 received daily CSF1Ri starting at day –5 and LLC-LUC, as well as 1 × 106 sorted naive NK cells, on day 
0. Metastatic load in the lungs was quantified by bioluminescence on resected lungs on day 15. Each 
symbol represents an individual mouse. Ctrl, n = 8; CSF1Ri, n = 10; CSF1Ri + NK, n = 5. **P < 0.01 (1-way 
ANOVA with Bonferroni’s correction). A representative experiment of 2 is shown.
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(BD Biosciences). For postoperative analgesia, Temgesic (Buprenorphine, Schering-Plough) was given 
s.c. at 0.1 mg/kg immediately after surgery and in drinking water at 10 μg/ml for 48 hours ad libitum. 
Three weeks after surgery, mice were anesthetized with 2.5% Attane and injected i.p. with 150 mg/kg 
D-luciferin (TBD-Biodiscovery). In our experience, s.c. LLC-LUC tumors typically give rise to metastasis 
to lungs, liver, and/or tumor-draining lymph nodes in 50%–70% of  the mice. The affected organs contain 
1–3 metastatic foci on average. For this reason, we determined the cumulative photon flux of  dissected 
lungs, liver, and tumor-draining lymph nodes using an IVIS 200 imaging system (PerkinElmer). The data 
are presented as sum of  luminescent signals from lung, liver, and 2 tumor-draining lymph nodes for each 
mouse. Mice with primary tumors below 200 mg at resection were not further analyzed for metastasis 
development. When interventions started after resection, mice were randomized based on the weight of  
the primary tumor before start of  interventions.
For spontaneous metastasis from orthotopic breast cancer, 1 × 105 4T1 cells in 50 μl PBS were injected 
into the second mammary fat pad of  BALB/c mice, and mice were sacrificed on day 23 or 25, as indicat-
ed. For counting metastases, India ink (Pelikan, 15% in PBS) was injected intratracheally and lungs were 
removed, washed with PBS, and fixed in Fekete’s solution (62% ethanol, 3.3% formaldehyde, 0.25 M acetic 
acid). Metastatic foci were counted in a blinded fashion using a dissecting microscope. Because 4T1 tumors 
induce metastasis with faster kinetics than LLC-LUC tumors, the size of  the primary tumors stayed below 
the legal limit until the endpoint; therefore, we did not perform surgery in the 4T1 model.
For experimental metastasis, C57BL/6 mice were injected i.v. into the tail vein with 5 × 105 LLC-LUC 
cells in 200 μl PBS. Mice were sacrificed on days mentioned in legends of  Figures 3, 4, and 5 and Supple-
mental Figures 8 and 9; bioluminescence was measured in dissected lungs as described above.
Treatment of  mice. To deplete CD8+ T cells, CD4+ T cells, or NK cells, mice were injected with 500 μg 
anti-CD8 (clone YTS169.4, hybridoma originally obtained from H. Waldmann, Oxford, United Kingdom), 
500 μg anti-CD4 (clone GK1.5, ATCC), or 200 μg anti-NK1.1 (clone PK136, ATCC), respectively. A single 
Figure 6. NK cells control metastatic seeding. Blockade of CSF1R results in loss of CSF1R-dependent myeloid cells and, consequently, of transpresent-
ed IL-15. This situation induces a paucity of NK cells and promotes metastasis. Administration of exogenous IL-15 to CSF1Ri-treated mice rescues NK 
cell numbers and reverses increased metastasis in the face of low numbers of myeloid cells.
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injection of  the respective antibody resulted in depletion of  >90% of  CD4+ or CD8+ T cells for at least 18 
days, as determined by flow cytometry (data not shown for CD4). Antibodies were injected as depicted in 
the experimental timelines. Anti-CD8, anti-CD4, and anti-NK1.1 antibodies were purified from hybridoma 
culture supernatant using protein G sepharose 4 Fast Flow (MilliporeSigma). Anti-CSF1R antibody (clone 
AFS98) was obtained from BioXCell and was used at 500 μg per dose. All antibodies were administered i.p. 
in 200 μl PBS. Full depletion of  the targeted population was confirmed by flow cytometry on blood 2 days 
after injection of  the antibody in every experiment.
CSF1Ri BLZ945 was supplied by Novartis Institutes for Biomedical Research (Emeryville, California, 
USA) and dissolved at 12.5 mg/ml in 20% Captisol as vehicle. CSF1Ri or vehicle were administered daily 
per os (p.o.) at 200 mg/kg.
IL-15 complexes were prepared by mixing recombinant murine IL-15 (Affymetrix eBioscience) and 
recombinant murine IL-15Rα (R&D Biosystems) in a 1:1 molar ratio and by subsequent incubation at 
37°C for 30 minutes as described (28). IL-15 complexes were administered i.p. at 4.5 μg/mouse in 200 
μl of  PBS.
For adoptive transfer of  NK cells, live CD45+CD3–NK1.1+ single cells were sorted using a FACS Mel-
ody (BD Biosciences) with a 100-μm nozzle from spleens from naive C57BL/6 mice. Sorted NK cells 
were >98% pure (data not shown). At the time point of  i.v. tumor cell injection, 1 × 106 NK cells were i.v. 
injected with 100 μl PBS.
Flow cytometry. Primary tumors were collected in PBS, cut into pieces, and digested for 45 minutes 
at 37°C in RPMI Medium containing 10% FBS, 1 mg/ml collagenase IV, and 2.6 μg/ml DNase I (both 
MilliporeSigma). Samples were washed with PBS by centrifugation for 5 minutes at 350 g, and the pel-
let was resuspended in PBS and filtered to remove debris. For surface staining, antibodies against the 
following proteins were used: CD3 (clone 17A2), CD4 (clone RM4-5), CD8α (clone 53-6.7), CD11b 
(clone M1/70), CD19 (clone 6D5), CD27 (clone LG.3A10), CSF1R (clone AFS98), CD45.2 (clone 
104), CD49b (clone DX5), CD69 (clone H1.2F3), DNAM-1 (clone 10E5), F4/80 (clone BM8), FasL 
(clone MFL3), FoxP3 (clone FJK.16s), KLRG1 (clone 2F1), Ly6C (clone HK1.4), Ly6G (clone 1A8), 
NK1.1 (clone PK136), and NKp46 (clone 29A1.4). For viability staining, Zombie Violet Fixable Viabil-
ity Kit was used. Anti-FoxP3 (FJK.16s) and FoxP3-staining buffers were purchased from eBioscience; 
all other antibodies and reagents mentioned above in this paragraph were obtained from BioLegend. 
Samples were incubated in PBS for 25 minutes at 4°C. For quantitative analysis, CountBright absolute 
counting beads were used (Thermo Fisher Scientific). In all staining, dead cells were excluded using 
Live/Dead fixable staining reagents (Invitrogen), and doublets were excluded by forward scatter A 
(FSC-A) versus FSC-H and side scatter A (SSC-A) versus SSC-H gating. Samples were acquired using 
a CyAn ADP 9 flow cytometer (Beckman Coulter) or FACS LSRII Fortessa (BD Biosciences) and ana-
lyzed using FlowJo v9.8.5 software (Tree Star Inc.).
IL-15 transpresentation assay. As a measure of  IL-15R signaling to NK cells, pSTAT5 was measured 
(25). NK1.1+CD3– cells were sorted from the spleen of  C57BL/6 mice and were stained after sorting 
with 10 μM Celltracker Violet (Invitrogen) according to the manufacturer’s instructions. NK1.1–CD-
11b+CD115+ and NK1.1–CD11b+CD115– cells were sorted from the spleen of  C57BL/6 or Il15ra–/– mice 
that were injected i.p. 24 hours before with 150 μg poly-IC (MilliporeSigma) in PBS. Only live singlets 
were considered for sorting. Cell sorting was performed with a FACSMelody (BD Biosciences) using a 
100-μm nozzle. Sorted cells had a purity >95%. Fifty-thousand NK cells were cultured with an equal 
number of  WT NK1.1–CD11b+CD115+ cells, WT NK1.1–CD11b+CD115– cells, Il15ra–/– NK1.1–CD-
11b+CD115+ cells, Il15ra–/– NK1.1–CD11b+CD115– cells, or with medium alone. Cultures were per-
formed in 96-well round-bottom plates in a volume of  150 μl medium (RPMI 1640 Medium supple-
mented with 10% FBS, 2 mM L-glutamine, penicillin, and streptomycin) for 30 minutes at 37°C. Cells 
were subsequently stained for pSTAT5 as described (62). Briefly, cells were collected and fixed with 2% 
paraformaldehyde for 20 minutes at 4°C. Cells were spun down, resuspended in 1 ml ice-cold methanol, 
and incubated for 20 minutes at 4°C. Cells were washed twice with 0.5% FCS in PBS and stained with 
anti-pSTAT5 (clone 47, BD Biosciences) for 45 minutes at 4°C. pSTAT5 expression was measured after 
gating on live, Celltracker Violet+ NK cells using a CyAn ADP 9 flow cytometer (Beckman Coulter) and 
FlowJo v9.8.5 software (Tree Star Inc.).
Statistics. For comparison of  2 experimental groups, 2-tailed Student’s t test with Welch’s correction 
was performed. More than 2 groups were compared using the 1-way ANOVA test with Bonferroni’s 
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correction. Frequencies of  metastases in the LLC-LUC model were compared with the χ2 test based on 
the frequencies in the control groups of  each experiment. All tests were performed with GraphPad Prism 
5.0 and GraphPad QuickCalcs (GraphPad Software). *P < 0.05, **P < 0.01, ***P < 0.005. Unless stated 
otherwise, data are shown as mean ± SD.
Study approval. Animal experiments were performed in accordance with the Swiss federal and cantonal 
regulations on animal protection and were approved by The Cantonal Veterinary Office Zurich (license 
number 65/2015 to MVDB).
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